@article{2294da3f747541549938724e871cd9b1,
title = "A phase I/II study of pembrolizumab (P) with gemcitabine (G) in patients (Pts) with previously-treated advanced non-small cell lung cancer (NSCLC): Phase I safety results.",
author = "Sanborn, \{Rachel E.\} and Duffy, \{Regan M.\} and Fisher, \{Brenda K\} and Perlewitz, \{Kelly Shea\} and Redmond, \{William L\} and Yoshinobu Koguchi and Fox, \{Bernard A.\}",
note = "e20605 Background: P, an anti-PD1 antibody active in advanced NSCLC, has optimal benefit in tumors with high PD-L1 expression. G may increase antigen cross-presentation and prime CD8 T cell responses via increased tumor cell apoptosis. The combination of antigen cross-presentation and T cell activation may have a synergistic effect with concurrent anti-PD1 immunotherapy.",
year = "2017",
month = may,
day = "20",
doi = "10.1200/jco.2017.35.15\_suppl.e20605",
language = "American English",
volume = "35",
journal = "Journal of Clinical Oncology",
}